Bardin Hill Management Partners’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bardin Hill Management Partners’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-388,022	Closed	-$268K	–	113
2020 Q4	$268K	Sell	388,022 -204,707	-35%	-$436K	0.06%	39
2020 Q3	$1.33M	Sell	592,729 -77,081	-12%	-$220K	0.35%	30
2020 Q2	$2.4M	Buy	669,810 +249,032	+59%	+$898K	0.88%	18
2020 Q1	$1.6M	Buy	420,778 +341,625	+432%	+$1.13M	0.35%	26
2019 Q4	$238K	Buy	+79,153	New	+$206K	0.04%	31

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Bardin Hill Management Partners's BMY.RT Position: Q1 2021 in Review

Bardin Hill Management Partners sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 388,022 shares — an estimated $268K sold.

Bardin Hill Management Partners first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $2.4M in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Bardin Hill Management Partners reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Bardin Hill Management Partners sold 388,022 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $268K.
Bardin Hill Management Partners first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Bardin Hill Management Partners's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $2.4M in Q2 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Bardin Hill Management Partners's 13F filing for Q1 2021, filed 14 May 2021.